AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11299845 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin followed by Docetaxel (A->T->CMF)
Number of subjects: 34
Study 11299845 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by Doxorubicin (T->A->CMF)
Number of subjects: 34
Study 9266270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (1 g)/Sulbactam (0.5 g)
Number of subjects: 81
Study 9266270 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam (2 g)
Number of subjects: 81
Study 8119065 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass operation (surgery-assigned group)
Number of subjects: 0
Study 8119065 — intervention group
Group type: COMPARATOR
Intervention: Diet treatment (control-assigned group)
Number of subjects: 0
Study 6480455 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 15.5 gm/M2
Number of subjects: 16
Study 6480455 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 13.5 gm/M2
Number of subjects: 16
Study 6480455 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 17.5 gm/M2
Number of subjects: 16
Study 6480455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 2 mg t.i.d. during treatment
Number of subjects: 16
Study 30273185 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNRB)
Number of subjects: 233
Study 30125052 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanova 4 g daily
Number of subjects: 13086
Study 30125052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13086
Study 27031491 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz sound stimulation
Number of subjects: 18
Study 27031491 — intervention group
Group type: COMPARATOR
Intervention: Visual stimulation using DVDs
Number of subjects: 18
Study 25240821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus paclitaxel
Number of subjects: 665
Study 25240821 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 665
Study 23031850 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education, household possessions, infant birth weight, child HIV infection, male sex
Number of subjects: 2387
Study 23031850 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 2387
Study 23031850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Apgar score at birth
Number of subjects: 2387
Study 23031850 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve maternal education and nutritional status, reduce mother-to-child transmission of HIV, and increase birth weight
Number of subjects: 2387
Study 20735822 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Ergonomics (PE)
Number of subjects: 81
Study 17625416 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 491
Study 17625416 — intervention group
Group type: COMPARATOR
Intervention: Open colposuspension
Number of subjects: 491
Study 17196275 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/d)
Number of subjects: 36
Study 17196275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15048162 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting tidal volume in acute lung injury or acute respiratory distress syndrome
Number of subjects: 0
Study 15048162 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal directed therapy
Number of subjects: 0
Study 15048162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C
Number of subjects: 0
Study 15048162 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate doses of steroids
Number of subjects: 0
Study 15048162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control of blood sugar
Number of subjects: 0
Study 10910421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 10910421 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study 8725851 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (50 mg three times daily)
Number of subjects: 20
Study 8725851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8725851 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 20
Study 1340780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 50 mg
Number of subjects: 30
Study 1340780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg
Number of subjects: 30
Study 1340780 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride)
Number of subjects: 30
Study 6726466 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg or more
Number of subjects: 0
Study 6726466 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg and greater
Number of subjects: 0
Study 6726466 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg
Number of subjects: 0
Study 6726466 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin B-6 supplementation
Number of subjects: 0
Study 6726466 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 intake between 5.5 and 7.6 mg/day (diet plus supplement as pyridoxine equivalents)
Number of subjects: 0
Study 31174397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program including stretching of hamstrings and progressive resistance exercise (PRE) targeting the lower extremities, 16 weeks (3 sessions per week) followed by a 16-week maintenance program (1 session per week)
Number of subjects: 37
Study 31174397 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (comparison group)
Number of subjects: 37
Study 28082159 — intervention group
Group type: COMPARATOR
Intervention: Lecture slides (LG)
Number of subjects: 73
Study 28082159 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosections (PG)
Number of subjects: 73
Study 28082159 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiology images (RG)
Number of subjects: 73
Study 24707921 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 HMCAS
Number of subjects: 126
Study 24707921 — intervention group
Group type: COMPARATOR
Intervention: NHMCAS
Number of subjects: 126
Study 24707921 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal HMCAS
Number of subjects: 126
Study 24707921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdense M2
Number of subjects: 126
Study 24707921 — intervention group
Group type: EXPERIMENTAL
Intervention: HMCAS proximal
Number of subjects: 126
Study 24707921 — intervention group
Group type: EXPERIMENTAL
Intervention: HMCAS full length
Number of subjects: 126
Study 23866945 — intervention group
Group type: EXPERIMENTAL
Intervention: POE-POP
Number of subjects: 0
Study 23866945 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 21346160 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion-extension method
Number of subjects: 96
Study 21346160 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (Control)
Number of subjects: 96
Study 19332958 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus amlodipine 10 mg
Number of subjects: 1078
Study 19332958 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg (monotherapy)
Number of subjects: 1078
Study 19332958 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg plus amlodipine 10 mg
Number of subjects: 1078
Study 16537682 — intervention group
Group type: EXPERIMENTAL
Intervention: saline/ghrelin infusion
Number of subjects: 9
Study 16537682 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine/saline
Number of subjects: 9
Study 16537682 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine/ghrelin
Number of subjects: 9
Study 16537682 — intervention group
Group type: COMPARATOR
Intervention: saline/saline
Number of subjects: 9
Study 16537682 — intervention group
Group type: COMPARATOR
Intervention: saline/ghrelin
Number of subjects: 9
Study 12683264 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (except amisulpride)
Number of subjects: 0
Study 12683264 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 12683264 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 12683264 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study 12683264 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone, Olanzapine, Quetiapine
Number of subjects: 0
Study 12683264 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 0
Study 10882582 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV)
Number of subjects: 72
Study 10882582 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)
Number of subjects: 72
Study 10882582 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods (cluster analysis, recursive partitioning, linear discriminant analysis)
Number of subjects: 72
Study 8622332 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (800 IU daily for first 546 patients; 400 IU daily for remainder)
Number of subjects: 2002
Study 8622332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2002
Study 1391111 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet administered to 21 patients
Number of subjects: 49
Study 1391111 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial enteral diet administered to 28 patients
Number of subjects: 49
Study 6399448 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized imagery of drinking situations associated with painful electric shock
Number of subjects: 0
Study 6399448 — intervention group
Group type: COMPARATOR
Intervention: Individualized imagery of drinking situations associated with sham shock
Number of subjects: 0
Study 6399448 — intervention group
Group type: EXPERIMENTAL
Intervention: General treatment program for alcoholism including relaxation training
Number of subjects: 0
Study 29768093 — intervention group
Group type: EXPERIMENTAL
Intervention: Kipping Pull-Up (KPU)
Number of subjects: 11
Study 29402303 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 0
Study 26031397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate and chlorhexidine diacetate
Number of subjects: 24
Study 26031397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate and chlorhexidine diacetate with reduced amounts of mint and menthol
Number of subjects: 24
Study 26031397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc chloride and essential oil
Number of subjects: 24
Study 26031397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc lactate, chlorhexidine and cetylpyridinium chloride
Number of subjects: 24
Study 26031397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24568148 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (direct grasping)
Number of subjects: 31
Study 24568148 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (indirect grasping)
Number of subjects: 31
Study 24568148 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (fixating)
Number of subjects: 31
Study 24568148 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (combination of tasks)
Number of subjects: 31
Study 24568148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no practice)
Number of subjects: 31
Study 22321357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (Continuing Active subjects)
Number of subjects: 163
Study 22321357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (Formerly Placebo subjects)
Number of subjects: 163
Study 20061358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (haemoglobin A(1C) <6.0%)
Number of subjects: 10194
Study 20061358 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard glucose control (haemoglobin A(1C) 7.0-7.9%)
Number of subjects: 10194
Study 20061358 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10194
Study 18004138 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg BID for 7 days followed by 75 mg BID for another 7 days
Number of subjects: 12
Study 18004138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15780963 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 65
Study 15780963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 11813623 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohyperthermic peritoneal perfusion (CHPP)
Number of subjects: 139
Study 11813623 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonormothermic peritoneal perfusion (CNPP)
Number of subjects: 139
Study 11813623 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 139
Study 9744643 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21 administered by continuous intravenous infusion for 48 hours in patients and healthy volunteers
Number of subjects: 0
Study 9744643 — intervention group
Group type: COMPARATOR
Intervention: rBPI21 administered intravenously in rats after 60% or 80% hepatectomy
Number of subjects: 0
Study 9744643 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to healthy volunteers
Number of subjects: 0
Study 8172096 — intervention group
Group type: EXPERIMENTAL
Intervention: Large amounts of endurance exercise (400 min/wk) + weight training (3 d/wk) + very-low-energy diet (3360-kJ/d)
Number of subjects: 23
Study 8172096 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate amounts of endurance exercise (200 min/wk) + weight training (3 d/wk) + very-low-energy diet (3360-kJ/d)
Number of subjects: 23
Study 8172096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise) + very-low-energy diet (3360-kJ/d)
Number of subjects: 23
Study 3054591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with preoperative radiotherapy (4 Gy for 5 days, total 20 Gy)
Number of subjects: 478
Study 3054591 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment only
Number of subjects: 478
Study 3054591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with preoperative radiotherapy
Number of subjects: 478
Study 30963229 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar enucleation of the prostate (MEP)
Number of subjects: 134
Study 30963229 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 134
Study 30963229 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 134
Study 30963229 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP
Number of subjects: 134
Study 31072710 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapeutic mild hypercapnia (TTMH) with target arterial carbon dioxide partial pressure between 50 and 55 mmHg
Number of subjects: 30
Study 31072710 — intervention group
Group type: COMPARATOR
Intervention: Standard carbon dioxide management (normocapnia)
Number of subjects: 30
Study 28500492 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg i.v.
Number of subjects: 83
Study 28500492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g i.v.
Number of subjects: 83
Study 28500492 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v.
Number of subjects: 83
Study 28500492 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Methylprednisolone, Paracetamol, Placebo)
Number of subjects: 83
Study 26135245 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccine formulations (2 doses)
Number of subjects: 0
Study 26135245 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccine formulations (3 doses)
Number of subjects: 0
Study 26135245 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccines (2 or 3 doses)
Number of subjects: 0
Study 26135245 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccines
Number of subjects: 0
Study 24094643 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV 250 mAs with hybrid iterative reconstruction (iDose)
Number of subjects: 44
Study 24094643 — intervention group
Group type: COMPARATOR
Intervention: 120 kV 250 mAs with filtered back projection (FBP)
Number of subjects: 44
Study 21452294 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg weekly (with or without a 4-week loading period)
Number of subjects: 311
Study 21452294 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 311
Study 21452294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 21452294 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (both groups)
Number of subjects: 311
Study 17433756 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic taping
Number of subjects: 15
Study 17433756 — intervention group
Group type: COMPARATOR
Intervention: Control taping
Number of subjects: 15
Study 17433756 — intervention group
Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study 16024183 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 and 0.2%)
Number of subjects: 14
Study 16024183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2 and 0.4%)
Number of subjects: 14
Study 16024183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) (15 and 30%)
Number of subjects: 14
Study 16024183 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (100% O2)
Number of subjects: 14
Study 12900133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose magnesium and low-dose lidocaine, infused over 3 days
Number of subjects: 32
Study 10875098 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (ampicillin)
Number of subjects: 36
Study 10875098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal fluid IL-6 measurement
Number of subjects: 36
Study 10875098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal fluid IL-8 measurement
Number of subjects: 36
Study 10875098 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal infections
Number of subjects: 36
Study 9104869 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) followed by Aerobic Training (AT)
Number of subjects: 20
Study 9104869 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 20
Study 9104869 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 7956612 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (30-60 mg/day)
Number of subjects: 18
Study 7956612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2852692 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg iv
Number of subjects: 15
Study 2852692 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DMP) 10 mg iv
Number of subjects: 15
Study 31354055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glyburide
Number of subjects: 28
Study 31354055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30489094 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reflection training
Number of subjects: 226
Study 30489094 — intervention group
Group type: COMPARATOR
Intervention: Coping skills training
Number of subjects: 226
Study 27875943 — intervention group
Group type: EXPERIMENTAL
Intervention: Thicker surfboards (higher volume)
Number of subjects: 20
Study 27875943 — intervention group
Group type: COMPARATOR
Intervention: Thinner surfboards (lower volume)
Number of subjects: 20
Study 27537707 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Listing (TL)
Number of subjects: 0
Study 27537707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 0
Study 27537707 — intervention group
Group type: COMPARATOR
Intervention: Non-Hoarding Community Controls (CC)
Number of subjects: 0
Study 24750544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 76
Study 24750544 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 76
Study 22460947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy (high-dose cytarabine combined with amsacrine or daunorubicin)
Number of subjects: 315
Study 22460947 — intervention group
Group type: COMPARATOR
Intervention: Standard consolidation and maintenance therapy (standard dose cytarabine and daunorubicin)
Number of subjects: 315
Study 22460947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy
Number of subjects: 315
Study 22460947 — intervention group
Group type: COMPARATOR
Intervention: Standard consolidation and maintenance therapy
Number of subjects: 315
Study 18718816 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation using the Heart Manual
Number of subjects: 26
Study 18718816 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation
Number of subjects: 26
Study 17329091 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 34
Study 17329091 — intervention group
Group type: EXPERIMENTAL
Intervention: General Exercise Reconditioning (GER) + IMT
Number of subjects: 34
Study 17329091 — intervention group
Group type: COMPARATOR
Intervention: Sham IMT
Number of subjects: 34
Study 15452803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue reduction surgery
Number of subjects: 40
Study 15452803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tongue reduction)
Number of subjects: 40
Study 12194637 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group (25 patients)
Number of subjects: 52
Study 12194637 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (27 patients)
Number of subjects: 52
Study 9498258 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon for 3 months (n = 47)
Number of subjects: 334